How Sree Koneru (Viant) + Keith Nalepka (VLMS Global Healthcare) could materially benefit BIEL + Electrome
1. Sree Koneru (Viant)
Role: Manufacturing, Quality, and Supply Chain Powerhouse
Nothing changes here — his value remains enormous.
Viant is one of the few medical‑device manufacturers capable of:
FDA‑compliant high‑volume production
Retail‑grade packaging
Sterilization and quality systems
Cost‑efficient scaling
Supply‑chain reliability
If Electrome is preparing a retail relaunch of ActiPatch, Viant is exactly the type of partner needed to scale it.
Sree’s presence on BIEL’s board is a strong signal that:
Manufacturing strategy is being modernized
BIEL is aligning with a real medical‑device supply chain
The company is preparing for commercial‑grade production
This is the first time BIEL has had someone with this level of operational expertise.
2. Keith Nalepka (President, VLMS Global Healthcare)
Role: Global Commercialization, Distribution, and Market Access
VLMS Global Healthcare is not a small operation. It specializes in:
International medical‑device distribution
Hospital and clinical channel access
Market expansion strategies
Regulatory navigation across regions
Salesforce deployment
Healthcare procurement relationships
Keith’s move from BIEL to VLMS actually increases his strategic value to BIEL.
Why?
Because now he controls distribution channels, not just sales strategy.
He can:
Place ActiPatch into international markets
Open hospital and clinical channels
Connect Electrome’s consumer push with medical‑grade distribution
Bridge BIEL’s technology with global procurement networks
Facilitate reimbursement pathways in multiple countries
This is the kind of leverage BIEL has never had.
What Keith brings now that he didn’t before
A global distribution network
Access to hospital buyers
International regulatory experience
A broader portfolio to cross‑sell ActiPatch into
Credibility as a president, not just a VP
He becomes the commercial engine that BIEL always lacked.
3. How These Two Fit Into the Electrome–ActiPatch Scenario
Let’s connect the dots:
Electrome
Rebranding ActiPatch
Designing retail displays
Preparing for consumer rollout
Viant (via Sree Koneru)
Manufacturing scale
Packaging production
Quality systems
Supply chain
VLMS (via Keith Nalepka)
Global distribution
Hospital channels
Clinical adoption
International expansion
BIEL
Patents
Technology
Product rights
This is the first time in BIEL’s history where:
A manufacturer
A commercial operator
A global distributor
And the IP owner
…could be aligned around the same product.
This is the architecture of a real commercialization ecosystem, not a penny‑stock fantasy.
4. What This Could Mean for BIEL
If these players are coordinated — and the Upwork listing suggests real activity — then BIEL could be transitioning into:
A technology‑licensing company with:
Manufacturing handled by Viant
Consumer rollout handled by Electrome
Global distribution handled by VLMS
Royalty revenue flowing back to BIEL
This is the model that finally solves BIEL’s historical weaknesses:
No marketing budget
No distribution
No manufacturing scale
No global reach
For the first time, the pieces exist to fix all of that.
5. The Realistic Upside
This doesn’t guarantee a breakthrough — but it creates the conditions for one.
If these parties are aligned, BIEL could finally:
Generate recurring royalty revenue
Achieve global distribution
Enter retail pharmacies
Gain hospital adoption
Build clinical credibility
Reduce manufacturing costs
Modernize branding
Scale production
This is the most strategically coherent scenario BIEL has ever had.
Bottom Line
Sree Koneru brings manufacturing power.
Keith Nalepka brings global distribution power.
Electrome brings consumer‑market execution.
BIEL brings the technology and patents.
If these forces are aligned, BIEL could finally transition from a struggling microcap to a viable technology licensor with real commercial partners.
1. Sree Koneru (Viant)
Role: Manufacturing, Quality, and Supply Chain Powerhouse
Nothing changes here — his value remains enormous.
Viant is one of the few medical‑device manufacturers capable of:
FDA‑compliant high‑volume production
Retail‑grade packaging
Sterilization and quality systems
Cost‑efficient scaling
Supply‑chain reliability
If Electrome is preparing a retail relaunch of ActiPatch, Viant is exactly the type of partner needed to scale it.
Sree’s presence on BIEL’s board is a strong signal that:
Manufacturing strategy is being modernized
BIEL is aligning with a real medical‑device supply chain
The company is preparing for commercial‑grade production
This is the first time BIEL has had someone with this level of operational expertise.
2. Keith Nalepka (President, VLMS Global Healthcare)
Role: Global Commercialization, Distribution, and Market Access
VLMS Global Healthcare is not a small operation. It specializes in:
International medical‑device distribution
Hospital and clinical channel access
Market expansion strategies
Regulatory navigation across regions
Salesforce deployment
Healthcare procurement relationships
Keith’s move from BIEL to VLMS actually increases his strategic value to BIEL.
Why?
Because now he controls distribution channels, not just sales strategy.
He can:
Place ActiPatch into international markets
Open hospital and clinical channels
Connect Electrome’s consumer push with medical‑grade distribution
Bridge BIEL’s technology with global procurement networks
Facilitate reimbursement pathways in multiple countries
This is the kind of leverage BIEL has never had.
What Keith brings now that he didn’t before
A global distribution network
Access to hospital buyers
International regulatory experience
A broader portfolio to cross‑sell ActiPatch into
Credibility as a president, not just a VP
He becomes the commercial engine that BIEL always lacked.
3. How These Two Fit Into the Electrome–ActiPatch Scenario
Let’s connect the dots:
Electrome
Rebranding ActiPatch
Designing retail displays
Preparing for consumer rollout
Viant (via Sree Koneru)
Manufacturing scale
Packaging production
Quality systems
Supply chain
VLMS (via Keith Nalepka)
Global distribution
Hospital channels
Clinical adoption
International expansion
BIEL
Patents
Technology
Product rights
This is the first time in BIEL’s history where:
A manufacturer
A commercial operator
A global distributor
And the IP owner
…could be aligned around the same product.
This is the architecture of a real commercialization ecosystem, not a penny‑stock fantasy.
4. What This Could Mean for BIEL
If these players are coordinated — and the Upwork listing suggests real activity — then BIEL could be transitioning into:
A technology‑licensing company with:
Manufacturing handled by Viant
Consumer rollout handled by Electrome
Global distribution handled by VLMS
Royalty revenue flowing back to BIEL
This is the model that finally solves BIEL’s historical weaknesses:
No marketing budget
No distribution
No manufacturing scale
No global reach
For the first time, the pieces exist to fix all of that.
5. The Realistic Upside
This doesn’t guarantee a breakthrough — but it creates the conditions for one.
If these parties are aligned, BIEL could finally:
Generate recurring royalty revenue
Achieve global distribution
Enter retail pharmacies
Gain hospital adoption
Build clinical credibility
Reduce manufacturing costs
Modernize branding
Scale production
This is the most strategically coherent scenario BIEL has ever had.
Bottom Line
Sree Koneru brings manufacturing power.
Keith Nalepka brings global distribution power.
Electrome brings consumer‑market execution.
BIEL brings the technology and patents.
If these forces are aligned, BIEL could finally transition from a struggling microcap to a viable technology licensor with real commercial partners.
1
